NICE recommends use of Sarclisa plus pomalidomide and dexamethasone for multiple myeloma .- Sanofi

The UK's NICE has issued final guidance on the use of Sarclisa (isatuximab), from Sanofi, administered as an intravenous infusion, plus pomalidomide and dexamethasone, which is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating relapsed and refractory multiple myeloma in adults. It is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if they have had 3 previous lines of treatment and the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.Clinical trial evidence suggests that isatuximab plus pomalidomide and dexamethasone delays the disease progressing and increases how long people live compared with pomalidomide plus dexamethasone. But, the trial is not finished so the benefit in the longer term is uncertain. The cost-effectiveness estimates for isatuximab plus pomalidomide and dexamethasone after 3 previous lines of treatment are uncertain because of limitations in the clinical data. The estimates are higher than what NICE normally considers an acceptable use of NHS resources. So isatuximab plus pomalidomide and dexamethasone cannot be recommended for routine use in the NHS.